The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
The mutant selection window and antimicrobial resistance
Abstract
The mutant selection window is an antimicrobial concentration range extending from the minimal concentration required to block the growth of wild-type bacteria up to that required to inhibit the growth of the least susceptible, single-step mutant. The upper boundary is also called the mutant prevention concentration (MPC). Placing antimicrobial concentrations inside the window is expected to enrich resistant mutant subpopulations selectively, whereas placing concentrations above the window is expected to restrict selective enrichment. Since window dimensions are characteristic of each pathogen-antimicrobial combination, they can be linked with antimicrobial pharmacokinetics to rank compounds and dosing regimens in terms of their propensity to enrich mutant fractions of bacterial populations. For situations in which antimicrobial concentrations cannot be kept above the window, restricting the enrichment of mutants requires combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica, K., & Zhao, X. (1997) · Microbiology and molecular biology reviews : MMBR · doi:10.1128/.61.3.377-392.1997 · Cited by 1,494
Self-citationFox, W., Ellard, G. A., & Mitchison, D. A. (1999) · PubMed · Cited by 797
Heffelfinger, J. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.10.1399 · Cited by 610
Pharmacodynamics of Levofloxacin: A New Paradigm for Early Clinical Trials
Preston, S. L. (1998) · JAMA · doi:10.1001/jama.279.2.125 · Cited by 589
Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia
Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C. S., Kibsey, P., Fleming, C., & Low, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012122 · Cited by 533
Thomas, J. K., Forrest, A., Bhavnani, S. M., Hyatt, J. M., Cheng, A., Ballow, C. H., & Schentag, J. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.521 · Cited by 507
Blaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
Pan, X. S., Ambler, J., Mehtar, S., & Fisher, L. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.10.2321 · Cited by 437
Drusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426
Wimberley, N., Faling, L. J., & Bartlett, J. G. (1979) · PubMed · doi:10.1164/arrd.1979.119.3.337 · Cited by 407
Cited by
Selection of Resistant Bacteria at Very Low Antibiotic Concentrations
Gullberg, E., Cao, S., Berg, O. G., Ilbäck, C., Sandegren, L., Hughes, D., & Andersson, D. I. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002158 · Cited by 1,654
Sublethal Antibiotic Treatment Leads to Multidrug Resistance via Radical-Induced Mutagenesis
Kohanski, M. A., DePristo, M. A., & Collins, J. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.003 · Cited by 985
Mechanisms of Resistance to Quinolones
Jacoby, G. A. (2005) · Clinical Infectious Diseases · doi:10.1086/428052 · Cited by 924
Evolutionary paths to antibiotic resistance under dynamically sustained drug selection
Toprak, E., Veres, A., Michel, J.-B., Chait, R., Hartl, D. L., & Kishony, R. (2012) · Nature Genetics · doi:10.1038/ng.1034 · Cited by 764
Mechanisms of drug resistance: quinolone resistance
Hooper, D. C., & Jacoby, G. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12830 · Cited by 716
Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., & Drusano, G. L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki079 · Cited by 549
Plasmid-Mediated Quinolone Resistance
Jacoby, G. A., Strahilevitz, J., & Hooper, D. C. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.plas-0006-2013 · Cited by 479
Dodd, M. C., Buffle, M.-O., & von Gunten, U. (2006) · Environmental Science & Technology · doi:10.1021/es051369x · Cited by 468
Persistence of antibiotic resistance in bacterial populations
Andersson, D. I., & Hughes, D. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00289.x · Cited by 435
Mutant Selection Window Hypothesis Updated
Drlica, K., & Zhao, X. (2007) · Clinical Infectious Diseases · doi:10.1086/511642 · Cited by 383
Self-citationPaul, T., Dodd, M. C., & Strathmann, T. J. (2010) · Water Research · doi:10.1016/j.watres.2010.03.002 · Cited by 368
Bell, G. (2017) · Annual Review of Ecology, Evolution, and Systematics · doi:10.1146/annurev-ecolsys-110316-023011 · Cited by 355
Drug interactions and the evolution of antibiotic resistance
Yeh, P. J., Hegreness, M. J., Aiden, A. P., & Kishony, R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2133 · Cited by 350
“, a region termed the mutant selection window (MSW”
Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin
Gumbo, T., Louie, A., Deziel, M. R., Liu, W., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01533-06 · Cited by 345
Accelerated evolution of resistance in multidrug environments
Hegreness, M., Shoresh, N., Damian, D., Hartl, D., & Kishony, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805965105 · Cited by 300
Gumbo, T., Louie, A., Deziel, M. R., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/424849 · Cited by 315
The Concept of an Ideal Antibiotic: Implications for Drug Design
Gajdács, M. (2019) · Molecules · doi:10.3390/molecules24050892 · Cited by 271
Minimising antibiotic resistance
Livermore, D. M. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70166-3 · Cited by 268
Antimicrobial Activity and Resistance: Influencing Factors
Li, J., Xie, S., Ahmed, S., Wang, F., Gu, Y., Zhang, C., Chai, X., Wu, Y., Cai, J., & Cheng, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00364 · Cited by 266
Dodd, M. C., Kohler, H.-P. E., & von Gunten, U. (2009) · Environmental Science & Technology · doi:10.1021/es8025424 · Cited by 261
Chono, S., Tanino, T., Seki, T., & Morimoto, K. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.011 · Cited by 164
The determinants of the antibiotic resistance process.
(2009) · Europe PMC (PubMed Central) · Cited by 126
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99
“However, the development of resistance may actually be less likely to occur as the larger doses may place the drug exposure level within the mutant prevention concentration window that precludes development of single step resistance [149, 150].”
Using Combination Therapy to Thwart Drug Resistance
Hill, J. A., & Cowen, L. E. (2015) · Future Microbiology · doi:10.2217/fmb.15.68 · Cited by 75
Coetzee, J. F., Cernicchiaro, N., Sidhu, P. K., & Kleinhenz, M. D. (2020) · Journal of Animal Science · doi:10.1093/jas/skaa109 · Cited by 12
Metadata
- Authors
- Drlica, K.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-06-12
- Volume
- 52
- Issue
- 1
- Pages
- 11-17
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2149166791
- Cited by
- 437
- References
- 41
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.